1526 related articles for article (PubMed ID: 15303499)
21. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
22. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant and salvage radiotherapy after radical prostatectomy.
Höcht S; Wiegel T; Schostak M; Hinkelbein W
Onkologie; 2002 Jun; 25(3):201-6. PubMed ID: 12119453
[TBL] [Abstract][Full Text] [Related]
24. Surgery or radiation: what is the optimal management for locally advanced prostate cancer?
Fletcher SG; Theodorescu D
Can J Urol; 2005 Feb; 12 Suppl 1():58-61; discussion 101-2. PubMed ID: 15780168
[TBL] [Abstract][Full Text] [Related]
25. A systematic overview of radiation therapy effects in breast cancer.
Rutqvist LE; Rose C; Cavallin-Ståhl E
Acta Oncol; 2003; 42(5-6):532-45. PubMed ID: 14596511
[TBL] [Abstract][Full Text] [Related]
26. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
27. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.
Martinez AA; Gustafson G; Gonzalez J; Armour E; Mitchell C; Edmundson G; Spencer W; Stromberg J; Huang R; Vicini F
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):316-27. PubMed ID: 12023135
[TBL] [Abstract][Full Text] [Related]
28. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer.
Jereczek-Fossa BA; Orecchia R
Radiother Oncol; 2007 Aug; 84(2):197-215. PubMed ID: 17532494
[TBL] [Abstract][Full Text] [Related]
29. Prostate brachytherapy: treatment strategies.
Stone NN; Stock RG
J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
Acta Oncol; 2007; 46(7):909-17. PubMed ID: 17917823
[TBL] [Abstract][Full Text] [Related]
31. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review.
Brundage M; Lukka H; Crook J; Warde P; Bauman G; Catton C; Markman BR; Charette M;
Radiother Oncol; 2002 Sep; 64(3):239-50. PubMed ID: 12242112
[TBL] [Abstract][Full Text] [Related]
32. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
Kupelian PA; Buchsbaum JC; Elshaikh MA; Reddy CA; Klein EA
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):629-34. PubMed ID: 14529766
[TBL] [Abstract][Full Text] [Related]
33. Updated results of high-dose rate brachytherapy and external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition.
Pellizzon AC; Salvajoli J; Novaes P; Maia M; Fogaroli R
Int Braz J Urol; 2008; 34(3):293-301. PubMed ID: 18601759
[TBL] [Abstract][Full Text] [Related]
34. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of high-dose-rate brachytherapy and external beam radiotherapy in the management of clinically localized prostate cancer.
Kotecha R; Yamada Y; Pei X; Kollmeier MA; Cox B; Cohen GN; Zaider M; Zelefsky MJ
Brachytherapy; 2013; 12(1):44-9. PubMed ID: 22831750
[TBL] [Abstract][Full Text] [Related]
36. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
37. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
38. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
39. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer.
Chin YS; Bullard J; Bryant L; Bownes P; Ostler P; Hoskin PJ
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):474-9. PubMed ID: 16909971
[TBL] [Abstract][Full Text] [Related]
40. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]